文献速递艾滋病与性传播感染病毒性肝炎

抗逆转录病毒治疗对赞比亚HIV感染成人肝纤维化的影响:合并与不合并HBV感染

Impact of Antiretroviral Therapy on Liver Fibrosis Among Human Immunodeficiency Virus-Infected Adults With and Without HBV Coinfection in Zambia.
PubMed 文献 · Clin Infect Dis · 2017-01-01

赞比亚463例HIV感染成人(61例合并HBV)启动含替诺福韦方案抗逆转录病毒治疗(ART),1年后瞬时弹性成像肝硬度中位变化-0.70 kPa(95%CI -3.0至+1.7),合并与不合并HBV者相似;

要点

  • 肝硬度中位变化-0.70 kPa(95%CI -3.0至+1.7),合并与不合并HBV者相似。

核心结论

  • HIV感染成人启动ART后提示显著纤维化/肝硬化的肝硬度升高比例下降,且不取决于HBV合并状态。
  • 合并HBV感染者1年时更可能出现显著纤维化/肝硬化。

研究设计与样本

  • 赞比亚HIV感染成人队列,分析463例(61例合并HBV),中位年龄35岁,53.7%为女性,基线中位CD4+计数240 cells/mm3。
  • 以瞬时弹性成像肝硬度测量(LSM,kPa)在ART启动时分类为无/轻微纤维化(相当于Metavir F0-F1)、显著纤维化(F2-F3)和肝硬化(F4),ART 1年后重复检测。
  • 按基线HBsAg阳性分层描述LSM变化和纤维化类别升降比例,用多变量logistic回归评估ART 1年时显著纤维化/肝硬化的相关因素。

主要发现

  • 97.6%患者接受含替诺福韦二吡呋酯的ART,符合国家推荐一线治疗。
  • LSM中位变化为-0.70 kPa(95%CI -3.0至+1.7),合并与不合并HBV感染相似。

临床怎么用

  • 对HIV感染成人启动含替诺福韦ART后,可预期肝硬度提示的显著纤维化/肝硬化比例下降。
  • 合并HBV感染、年龄较大和男性患者1年时显著纤维化/肝硬化风险更高,应加强纤维化监测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: We investigated changes in hepatic fibrosis, based on transient elastography (TE), among human immunodeficiency virus (HIV)-infected patients with and without hepatitis B virus (HBV) coinfection on antiretroviral therapy (ART) in Zambia. METHODS: Patients' liver stiffness measurements (LSM; kiloPascals [kPa]) at ART initiation were categorized as no or minimal fibrosis (equivalent to Metavir F0-F1), significant fibrosis (F2-F3), and cirrhosis (F4). TE was repeated following 1 year of ART. Stratified by HBV coinfection status (hepatitis B surface antigen positive at baseline), we described LSM change and the proportion with an increase/decrease in fibrosis category. Using multivariable logistic regression, we assessed correlates of significant fibrosis/cirrhosis at 1 year on ART. RESULTS: Among 463 patients analyzed (61 with HBV coinfection), median age was 35 years, 53.7% were women, and median baseline CD4+ count was 240 cells/mm3. Nearly all (97.6%) patients received tenofovir disoproxil fumarate-containing ART, in line with nationally recommended first-line treatment. The median LSM change was -0.70 kPa (95% confidence interval, -3.0 to +1.7) and was similar with and without HBV coinfection. Significant fibrosis/cirrhosis decreased in frequency from 14.0% to 6.7% (P < .001). Increased age, male sex, and HBV coinfection predicted significant fibrosis/cirrhosis at 1 year (all P < .05). CONCLUSION: The percentage of HIV-infected Zambian adults with elevated liver stiffness suggestive of significant fibrosis/cirrhosis decreased following ART initiation-regardless of HBV status. This suggests that HIV infection plays a role in liver inflammation. HBV-coinfected patients were more likely to have significant fibrosis/cirrhosis at 1 year on ART. CLINICAL TRIALS REGISTRATION: NCT02060162.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Vinikoor MJ, Sinkala E, Chilengi R, et al. Impact of Antiretroviral Therapy on Liver Fibrosis Among Human Immunodeficiency Virus-Infected Adults With and Without HBV Coinfection in Zambia. Clin Infect Dis. 2017. PMID: 28158504. doi:10.1093/cid/cix122

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。